Author Interviews, Cannabis, Opiods / 01.03.2017
Medical Cannabis May Be Effective Substitute for Opioids
MedicalResearch.com Interview with:
[caption id="attachment_32519" align="alignleft" width="200"]
Philippe Lucas[/caption]
Philippe Lucas
VP, Patient Research & Access, Tilray
Graduate Researcher, Centre for Addictions Research of BC
MedicalResearch.com: What is the background for this study?
Response: In 2001 Canada become one of the first nations to develop a federally regulated program to allow access to cannabis for medical purposes with the launch of the Marihuana Medical Access Regulations (MMAR). The program has undergone numerous convolutions, culminating in the establishment by Health Canada of the Marihuana for Medical Purposes Regulations (MMPR) in 2014, which was replaced by the Access to Cannabis for Medical Purposes (ACMPR) in 2016.
One of the primary changes in the new program(s) has been to move from a single Licensed Producer (LP) of cannabis to multiple large-scale Licensed Producers. This is the first comprehensive survey of patients enrolled in the MMPR/ACMPR, and with 271 complete responses, it’s the largest survey of federally-authorized medical cannabis patients to date.
Philippe Lucas[/caption]
Philippe Lucas
VP, Patient Research & Access, Tilray
Graduate Researcher, Centre for Addictions Research of BC
MedicalResearch.com: What is the background for this study?
Response: In 2001 Canada become one of the first nations to develop a federally regulated program to allow access to cannabis for medical purposes with the launch of the Marihuana Medical Access Regulations (MMAR). The program has undergone numerous convolutions, culminating in the establishment by Health Canada of the Marihuana for Medical Purposes Regulations (MMPR) in 2014, which was replaced by the Access to Cannabis for Medical Purposes (ACMPR) in 2016.
One of the primary changes in the new program(s) has been to move from a single Licensed Producer (LP) of cannabis to multiple large-scale Licensed Producers. This is the first comprehensive survey of patients enrolled in the MMPR/ACMPR, and with 271 complete responses, it’s the largest survey of federally-authorized medical cannabis patients to date.















